Navigation Links
Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President
Date:10/21/2010

developing non-invasive, topically delivered products. The Company's innovative-patented Transdel™ cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier.  Ketotransdel®, the Company's lead pain product candidate, has completed a Phase 3 clinical trial and utilizes the Transdel™ technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel™ platform technology to expand and create a portfolio of topical products for a variety of indications.  The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products.  For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel®; the Company's ability to obtain regulatory approval to market Ketotransdel; and the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the FDA may not agree with the Company's interpretation of the results of the Phase 3 clinical trial for Ketotransdel or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; t
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
3. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
4. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
5. Transdel Pharmaceuticals Announces Management Reorganization
6. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Wednesday, October 29, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Wednesday, October 29 1:30 ...
(Date:10/18/2014)... 18, 2014  In a policy paper ... the nation,s largest lesbian, gay, bisexual and transgender ... of Truvada for Pre-Exposure Prophylaxis (PrEP). PrEP is ... prevent the spread of a disease or infection ... name anti-HIV drug combination currently approved for PrEP, ...
(Date:10/17/2014)... AUSTIN, Texas , Oct. 17, 2014  Hanger, ... it plans to report its results of operations for ... 6, 2014 after the market closes.  A conference call ... 9:00 a.m., ET, on Friday, November 7, 2014. Those ... be available until Friday, November 14, 2014 by dialing ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... International, Inc. (NYSE: VRX ) (TSX: ... ALXA ) has received a Complete ... Drug Administration (FDA) regarding Alexza,s New Drug Application ... Staccato® (loxapine) inhalation aerosol, 5 mg and 10 ...
... Oct. 8 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... will assume the position of Chief Executive Officer following the ... and as a Director, effective November 1, 2010, due to ... to thank Mr. Doshi for his many contributions during his ...
Cached Medicine Technology:Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA 2Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA 3Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 2Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 3Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 4
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
(Date:10/20/2014)... Cleveland, Ohio (PRWEB) October 20, 2014 Unveiled ... Affairs’ new Strategic Direction Scorecard conservatively estimates member hospital ROI ... dollar spent on dues, The Center provides $12.50 in value ... ROI is (Member Value – Member Dues)/Member Dues. , ... get at this number and we think the methodology is ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
(Date:10/19/2014)... York (PRWEB) October 19, 2014 Dr. ... Population Fund, welcomes news of a ceasefire agreement that ... more than 200 girls who were kidnapped from the ... have languished in captivity long enough, and it is ... and communities," stated Dr. Osotimehin. , "We owe it ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... years later, study finds , MONDAY, Sept. 14 (HealthDay ... go into combat are more likely to develop high ... serve in supporting roles, a new military study finds. ... a unique risk factor for newly reported hypertension," Nisara ...
... weakened immune systems should worry, study says , MONDAY, Sept. ... you may want to rethink that daily shower. , New ... a type that can cause lung disease in people whose ... "blasted out of the showerhead and inhaled by the person ...
... ... Louis , ... 2009 -- , , ,WHO: American Association of Radon Scientists and Technologists, , ,WHAT: ... Station Marriott (near Scottrade Center) ,One St. Louis Union Station, , ,WHY: Radon ...
... , , HOPKINTON, Mass., ... ), the world leader in information infrastructure solutions, today ... systems with more than 25,000 healthcare provider customers, has ... EMC, RSA and VMware solutions. As a result, ...
... , , , ITASCA, Ill., ... savings at the JEWEL-OSCO grocery checkout. , , ... pharmacy will receive a special invitation to save a total ... steps to avoid serious complications that can result from certain other illnesses or health ...
... , , LISLE, Ill., ... ten percent of Americans face dangerous drinking water, the Water Quality Association ... , , On Sunday, the newspaper reported results of ... waters." Among its findings: , , Ten ...
Cached Medicine News:Health News:Combat Exposure Tied to Chronic High Blood Pressure 2Health News:Showerheads Harbor a Bounty of Germs 2Health News:Showerheads Harbor a Bounty of Germs 3Health News:21st International Radon Symposium 2Health News:eClinicalWorks Utilizes EMC to Manage Business Expansion and Reduce Costs 2Health News:eClinicalWorks Utilizes EMC to Manage Business Expansion and Reduce Costs 3Health News:JEWEL-OSCO PHARMACY Offers Grocery Savings to Flu Shot Customers 2Health News:Home Filtering Systems Provide Best Drinking Water Protection 2
Cytomegalovirus IgM ELISA....
Microforceps: Diamond Dusted Micro Pic Forceps...
Ultra-fine pointed forceps with diamond dusting on inner tip surface for enhanced grasping of tissue. Ideal for fine membrane grasping....
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Medicine Products: